Treatment for gpa as per this pdf only
Reading File
Running Command
python3 -c " import pdfplumber with pdfplumber.open('/home/daytona/workspace/attachments/286b2caa-bdc6-4052-9c81-8982f6581a0d/30.full.pdf') as pdf: print(f'Total pages: {len(pdf.pages)}') for i, page in enumerate(pdf.pages): text = page.extract_text() print(f'--- PAGE {i+1} ---') print(text) print() "
Here is a comprehensive summary of Treatment for GPA (Granulomatosis with Polyangiitis) as per the EULAR 2022 recommendations (Hellmich et al., Ann Rheum Dis 2024;83:30-47):
Treatment of GPA - EULAR 2022 Recommendations
REMISSION INDUCTION
A. Organ-threatening or Life-threatening GPA (Recommendation 3)
- First-line: Combination of high-dose glucocorticoids (GCs) + Rituximab (RTX) OR Cyclophosphamide (CYC)
- RTX is preferred in relapsing disease
- RTX is also preferred in patients wishing to preserve fertility (male or female), and in those with previous high CYC exposure
- RTX dosing (RAVE protocol): 375 mg/m² per week × 4 weeks OR 1 g at weeks 0 and 2 (both comparable efficacy)
- RTX biosimilars have similar efficacy to the originator
B. Non-organ-threatening / Non-life-threatening GPA (Recommendation 4)
- First-line: Combination of GCs + RTX
- Alternatives to RTX:
- Methotrexate (MTX) - can be continued if used to induce remission
- Mycophenolate mofetil (MMF) - especially if RTX is contraindicated/not tolerated
- CYC is not first-line here; may be considered only when RTX, MTX, and MMF cannot be used
GLUCOCORTICOID DOSING (Recommendation 5)
| Weeks | <50 kg | 50-75 kg | >75 kg |
|---|---|---|---|
| 1* | 50 mg | 60 mg | 75 mg |
| 2 | 25 mg | 30 mg | 40 mg |
| 3-4 | 20 mg | 25 mg | 30 mg |
| 5-6 | 15 mg | 20 mg | 25 mg |
| 7-8 | 12.5 mg | 15 mg | 20 mg |
| 9-10 | 10 mg | 12.5 mg | 15 mg |
| 11-12 | 7.5 mg | 10 mg | 12.5 mg |
| 13-14 | 6 mg | 7.5 mg | 10 mg |
| 15-18 | 5 mg | 5 mg | 7.5 mg |
| 19-52 | 5 mg | 5 mg | 5 mg |
(All doses are prednisolone equivalent/day)
*Consider IV methylprednisolone 1-3 g on days 1-3 for severely active disease (eGFR <50 mL/min/1.73 m² and/or diffuse alveolar haemorrhage)
- Target: 5 mg/day by 4-5 months
- IV methylprednisolone pulses should be limited to severe organ-threatening disease (active renal involvement with eGFR <50, or DAH); no routine use
AVACOPAN (Recommendation 6) - NEW 2022
- Avacopan 30 mg twice daily (oral C5a receptor inhibitor) + RTX or CYC may be considered as part of a strategy to substantially reduce GC exposure
- Especially indicated in:
- Patients at risk of GC-related adverse effects
- Active glomerulonephritis with rapidly declining kidney function (better renal recovery shown vs GC in the ADVOCATE trial)
- Remission at week 26: avacopan 72.3% vs GC 70.1% (comparable)
- Sustained remission at week 52: avacopan 65.7% vs GC 54.9% (superior)
- Stop avacopan after 6-12 months - no data beyond 1 year; longer-term use not recommended
PLASMA EXCHANGE (Recommendation 7)
- May be considered in patients with serum creatinine >300 µmol/L due to active glomerulonephritis (reduced from >500 µmol/L threshold in 2016 guidelines)
- Not routinely recommended for alveolar haemorrhage in GPA
- PLEX reduces ESKD risk at 12 months but increases serious infections - use requires individual risk-benefit discussion
- PLEX is recommended for patients with anti-GBM antibody overlap
REFRACTORY GPA (Recommendation 8)
- Thorough reassessment of disease status and comorbidities
- Consider switching from CYC to RTX or vice versa
- RTX + CYC combination considered by many centres
- IV immunoglobulins (IVIG) can be an option for persistent disease with increased infection risk
- These patients should be managed at vasculitis expert centres
REMISSION MAINTENANCE
GPA/MPA Maintenance (Recommendation 9)
- First-line: Rituximab - recommended after induction with either RTX or CYC
- RTX regimen: 500 mg every 6 months (preferred fixed schedule); higher dose (1 g) or shorter interval (every 4 months) may be considered for patients who relapse on 500 mg q6 months
- Alternatives to RTX:
- Azathioprine (AZA)
- Methotrexate (MTX)
- MMF (if intolerance/contraindications to RTX, AZA, MTX)
- Leflunomide (in GPA with intolerance to all above drugs)
- T/S (trimethoprim-sulfamethoxazole) does not reduce relapse risk; not recommended for relapse prevention
- Belimumab + AZA: no benefit shown in RCT
Duration of Maintenance (Recommendation 10)
- 24-48 months for new-onset disease
- Longer duration should be considered in:
- Relapsing patients
- Those with increased relapse risk (GPA > MPA; PR3-ANCA positive; ANCA positivity persisting in remission; B cell repopulation <12 months after RTX; respiratory tract involvement)
- Balance against patient preferences and immunosuppression risks
MONITORING DURING TREATMENT
Recommendation 15
- Structured clinical assessment (using BVAS scoring) should drive treatment decisions - not ANCA or CD19+ B cell testing alone
- ANCA/B cell counts have insufficient predictive value to guide individual patient decisions
Recommendation 16
- Measure serum immunoglobulin levels before each course of RTX to detect secondary immunodeficiency (hypogammaglobulinaemia develops in 21% after 36 months of RTX)
INFECTION PROPHYLAXIS (Recommendation 17)
- Trimethoprim-sulfamethoxazole (T/S) 800/160 mg on alternate days or 400/80 mg daily is recommended for all GPA patients receiving:
- CYC
- RTX
- GCs ≥30 mg/day for ≥4 weeks
- Purpose: Prophylaxis against Pneumocystis jirovecii pneumonia (PJP) and other infections
- Continue T/S for ~3 months after last CYC dose; ~6 months after last RTX dose or until B cell reconstitution
- Alternatives if T/S not tolerated: dapsone, atovaquone, aerosolised pentamidine
OVERARCHING PRINCIPLES
- Shared decision-making between patient and physician (considering efficacy, safety, costs)
- Patient education on disease, warning symptoms, treatment side effects
- Periodic screening for treatment-related adverse effects and comorbidities (cardiovascular risk, osteoporosis, CKD, bladder cancer if on CYC)
- Multidisciplinary management at centres with vasculitis expertise; access to clinical trials important for relapsing/refractory disease
Source: Hellmich B, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis 2024;83:30-47.
In induction phase which to choose rtx or cyc
Based on the PDF you shared (EULAR 2022), here is a direct answer:
RTX vs CYC for Induction in GPA - Decision Guide
Both are equally effective for new-onset GPA
RTX was non-inferior to CYC in two high-quality RCTs (RAVE and RITUXVAS trials) for new-onset GPA/MPA.
Choose RITUXIMAB when:
| Situation | Reason |
|---|---|
| Relapsing disease | RTX is preferred (higher remission rates at 6 & 12 months vs CYC in relapsing patients - RAVE trial) |
| Childbearing potential (male or female) | CYC reduces ovarian reserve, causes premature ovarian failure, male infertility |
| Previous high CYC exposure | Cumulative CYC increases malignancy risk |
| Concern about long-term toxicity | CYC linked to bladder cancer, bone marrow failure, myelodysplastic syndrome, other malignancies |
| RTX already used for induction | Repeated CYC courses increase cancer risk further |
Choose CYCLOPHOSPHAMIDE when:
| Situation | Reason |
|---|---|
| Severe renal failure (some centres prefer it) | RTX pharmacokinetics in severe renal failure are less studied; some task force members prefer CYC in this setting |
| Diffuse alveolar haemorrhage (DAH) with severe renal disease | Same reasoning as above (individual preference) |
| RTX contraindicated or unavailable | e.g., prior severe allergic reaction to RTX |
| Non-organ-threatening disease where RTX/MTX/MMF cannot be used | CYC is last-resort alternative in this setting |
Note: RTX and CYC have comparable outcomes in severe disease including renal involvement and DAH (PEXIVAS trial included both agents) - the preference for CYC in severe renal/DAH is not evidence-based but practice-based per the task force.
The Trend: RTX is Increasingly Preferred
The PDF explicitly states:
"There has been an increasing preference for RTX over CYC, mostly because of concerns about long-term safety of CYC."
"The use of RTX is lowering CYC exposure and reducing the risk of malignancy in patients with AAV."
Summary Algorithm (from the PDF)
New-onset GPA with organ/life-threatening disease
↓
RTX or CYC (both acceptable)
↓
Prefer RTX if: relapsing disease,
childbearing potential, prior CYC exposure,
safety concerns
Relapsing GPA → RTX preferred
Non-organ-threatening GPA → RTX recommended
(MTX or MMF as alternatives, NOT CYC first-line)
Bottom line from the PDF: For new-onset GPA, either agent is acceptable. RTX is the preferred choice in relapsing disease and whenever long-term toxicity is a concern. CYC should be reserved for situations where RTX cannot be used, except in selected severe renal/DAH cases where some clinicians still prefer it.
This is a shared conversation. Sign in to Orris to start your own chat.